ATE330937T1 - Glyburid-zusammensetzung - Google Patents

Glyburid-zusammensetzung

Info

Publication number
ATE330937T1
ATE330937T1 AT01900328T AT01900328T ATE330937T1 AT E330937 T1 ATE330937 T1 AT E330937T1 AT 01900328 T AT01900328 T AT 01900328T AT 01900328 T AT01900328 T AT 01900328T AT E330937 T1 ATE330937 T1 AT E330937T1
Authority
AT
Austria
Prior art keywords
glyburide
composition
glyburide composition
Prior art date
Application number
AT01900328T
Other languages
English (en)
Inventor
Gillian Cave
Sarah J Nicholson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE330937T1 publication Critical patent/ATE330937T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01900328T 2000-01-14 2001-01-04 Glyburid-zusammensetzung ATE330937T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14

Publications (1)

Publication Number Publication Date
ATE330937T1 true ATE330937T1 (de) 2006-07-15

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900328T ATE330937T1 (de) 2000-01-14 2001-01-04 Glyburid-zusammensetzung

Country Status (37)

Country Link
US (2) US20010036479A1 (de)
EP (1) EP1250321B1 (de)
JP (1) JP4787446B2 (de)
KR (1) KR100739906B1 (de)
CN (1) CN1210258C (de)
AR (1) AR031547A1 (de)
AT (1) ATE330937T1 (de)
AU (1) AU771705B2 (de)
BG (1) BG65782B1 (de)
BR (1) BR0107564A (de)
CA (1) CA2397294C (de)
CY (1) CY1106328T1 (de)
CZ (1) CZ20022429A3 (de)
DE (1) DE60120916T2 (de)
DK (1) DK1250321T3 (de)
EE (1) EE05020B1 (de)
ES (1) ES2264967T3 (de)
GE (1) GEP20043299B (de)
HU (1) HU228825B1 (de)
IL (2) IL150383A0 (de)
LT (1) LT5024B (de)
LV (1) LV12914B (de)
MX (1) MXPA02006835A (de)
MY (1) MY128577A (de)
NO (1) NO328152B1 (de)
NZ (1) NZ519920A (de)
PT (1) PT1250321E (de)
RO (1) RO121381B1 (de)
RU (1) RU2244707C2 (de)
SK (1) SK286925B6 (de)
TN (1) TNSN01005A1 (de)
TR (1) TR200201798T2 (de)
TW (1) TWI287989B (de)
UA (1) UA73968C2 (de)
UY (1) UY26529A1 (de)
WO (1) WO2001051463A1 (de)
ZA (1) ZA200205528B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
EP1465628A2 (de) * 2002-03-21 2004-10-13 Teva Pharmaceutical Industries Ltd. Pioglitazon in form feiner partikel
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
TWI339586B (en) 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
RU2359677C2 (ru) * 2004-04-29 2009-06-27 Лотус Фармасьютикал Ко., Лтд Оральные таблетки с модифицированным высвобождением и способ их получения
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
KR101452518B1 (ko) 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
CN101287467B (zh) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
WO2007131930A1 (en) * 2006-05-13 2007-11-22 Novo Nordisk A/S Tablet formulation comprising repaglinide and metformin
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
EP1967182A1 (de) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung mit einem Rosiglitazonsalz
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US8883852B2 (en) 2008-10-22 2014-11-11 University of Pittburgh—Of the Commonwealth System of Higher Education Radioprotective agents
US20110014284A1 (en) 2009-02-13 2011-01-20 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP2520298A1 (de) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmazeutische Zusammensetzung enthaltend Sulfonylureas (Glibenclamid) oder Meglitinides zur Behandlung von Hyperglykämie oder zur Wachstumsförderung eines Frühgeborenen
CN102743354A (zh) * 2012-07-31 2012-10-24 南京正科制药有限公司 瑞格列奈片及其制备方法
CN103142521B (zh) * 2013-03-21 2014-06-25 西南药业股份有限公司 格列本脲片及其制备方法
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN104127423A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列喹酮衍生物及其制备方法和应用
EP3609500B1 (de) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Behandlung von adipozyten
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
WO2022187567A2 (en) 2021-03-04 2022-09-09 Biogen Chesapeake Llc Low-sorbing glyburide formulation and methods
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru) 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
AU671965B2 (en) * 1991-12-05 1996-09-19 Alfatec-Pharma Gmbh Pharmaceutically Applicable Nanosol and Process for Preparing The Same
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
TR199903057T2 (xx) 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
DK0996429T3 (da) * 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
CN1210258C (zh) 2005-07-13
RU2244707C2 (ru) 2005-01-20
MXPA02006835A (es) 2003-01-28
ES2264967T3 (es) 2007-02-01
JP2003519681A (ja) 2003-06-24
DE60120916T2 (de) 2007-02-15
EP1250321A1 (de) 2002-10-23
LV12914B (en) 2003-01-20
KR100739906B1 (ko) 2007-07-16
EP1250321B1 (de) 2006-06-21
DK1250321T3 (da) 2006-07-31
NO20023367L (no) 2002-09-04
WO2001051463A1 (en) 2001-07-19
CZ20022429A3 (cs) 2003-06-18
GEP20043299B (en) 2004-03-10
BG65782B1 (bg) 2009-11-30
RU2002121626A (ru) 2004-01-10
CY1106328T1 (el) 2011-10-12
US20010036479A1 (en) 2001-11-01
CA2397294A1 (en) 2001-07-19
US6830760B2 (en) 2004-12-14
NO328152B1 (no) 2009-12-21
BR0107564A (pt) 2002-10-01
LT5024B (lt) 2003-06-25
NZ519920A (en) 2004-06-25
HU228825B1 (en) 2013-05-28
ZA200205528B (en) 2003-10-10
UA73968C2 (en) 2005-10-17
HUP0203852A3 (en) 2005-05-30
NO20023367D0 (no) 2002-07-12
PT1250321E (pt) 2006-09-29
TWI287989B (en) 2007-10-11
UY26529A1 (es) 2001-08-27
US20030185880A1 (en) 2003-10-02
PL356210A1 (en) 2004-06-14
DE60120916D1 (de) 2006-08-03
KR20020073169A (ko) 2002-09-19
CA2397294C (en) 2011-03-22
CN1395560A (zh) 2003-02-05
EE200200393A (et) 2003-10-15
AR031547A1 (es) 2003-09-24
BG106870A (en) 2003-03-31
SK9832002A3 (en) 2003-07-01
RO121381B1 (ro) 2007-04-30
IL150383A0 (en) 2002-12-01
AU771705B2 (en) 2004-04-01
LT2002085A (en) 2003-01-27
AU2474001A (en) 2001-07-24
TR200201798T2 (tr) 2002-11-21
TNSN01005A1 (en) 2005-11-10
IL150383A (en) 2007-03-08
HUP0203852A2 (hu) 2003-04-28
SK286925B6 (sk) 2009-07-06
EE05020B1 (et) 2008-06-16
JP4787446B2 (ja) 2011-10-05
MY128577A (en) 2007-02-28

Similar Documents

Publication Publication Date Title
DK1250321T3 (da) Glyburidsammensætning
IS2932B (is) Fúlvestrant samsetning
DE60134423D1 (de) Flammhemmende polycarbonat-polyester zusammensetzung
ATE303787T1 (de) Schergelzusammensetzungen
DK1524266T3 (da) Farmaceutisk sammensætning
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
PT1315485E (pt) Composição catártica
AR028197A1 (es) Composiciones antitranspirantes
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DE60106275T8 (de) Dermatologische zusammensetzung
DE60112317D1 (de) Pestizide zusammensetzung
DE50114386D1 (de) Ng
NO20030917D0 (no) Anvendelse
DE60125415D1 (de) Formeinsatz
DE60138268D1 (de) Ckware
DE60133154D1 (de) Antistatische Zusammensetzung
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE60116858D1 (de) Zusammensetzung
DE60104016D1 (de) Pestizide zusammensetzung
ATE372338T1 (de) Deshalogenverbindungen
NO20030303D0 (no) Kalsilytiske forbindelser
NO20031837L (no) Kalsilytiske forbindelser
NO20023508D0 (no) Kalsilyttiske forbindelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250321

Country of ref document: EP